Truist Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Truist Financial’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,339	Closed	-$688K	–	2877
2021 Q3	$688K	Sell	12,339 -29	-0.2%	-$1.43K	﹤0.01%	1828
2021 Q2	$529K	Sell	12,368 -12	-0.1%	-$495	﹤0.01%	2003
2021 Q1	$517K	Buy	12,380 +24	+0.2%	+$1.11K	﹤0.01%	1947
2020 Q4	$575K	Sell	12,356 -6,101	-33%	-$285K	﹤0.01%	1784
2020 Q3	$784K	Buy	18,457 +56	+0.3%	+$2.45K	﹤0.01%	1477
2020 Q2	$883K	Buy	18,401 +8	+0%	+$399	﹤0.01%	1342
2020 Q1	$846K	Buy	18,393 +16	+0.1%	+$803	﹤0.01%	1322
2019 Q4	$1.1M	Buy	+18,377	New	+$1.1M	﹤0.01%	1390

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Truist Financial's EGRX Position: Q4 2021 in Review

Truist Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2021, closing a stake of 12,339 shares — an estimated $688K sold.

Truist Financial first reported a position in EGRX in Q4 2019 and held it in 8 quarters. The position peaked at $1.1M in Q4 2019. 162 funds tracked by Wall St. Rank hold EGRX as of Q4 2021.

Truist Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Truist Financial sold 12,339 Eagle Pharmaceuticals, Inc. shares in Q4 2021, an estimated $688K.
Truist Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Truist Financial's Eagle Pharmaceuticals, Inc. position peaked at $1.1M in Q4 2019.
162 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.